MUSTANG BIO INC
MBIONASDAQTrading Snapshot
- Day Range
- $0.52 – $0.53
- 52-Week Range
- $0.47 – $1.85
- Volume
- $2.13B
- Avg Volume
- $2.25B
- Shares Outstanding
- 7.6M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $321,661
- Last Q Revenue
- $85,277
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.46
- Dividend Yield
- —
- Dilution (1yr)
- −16.0%
Why Investors Own MBIO
- ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MUSTANG BIO INC
MBIO
StockOtter · stockotter.spaceAbout MUSTANG BIO INC
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
MUSTANG BIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift MBIO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
MUSTANG BIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.